第一组肺动脉高压中肺动脉楔压升高的特征分析
本研究基于PVDOMICS队列,评估经 adjudicated 的第一组肺动脉高压患者中静息肺动脉楔压(PAWP)>15 mm Hg 的比例及特征。325例中15%存在高PAWP,其左心房功能和运动储备优于Cpc-PH HFpEF,代谢组学接近第一组PH。结果提示仅用静息PAWP区分第一组PH与HFpEF存在局限。
要点
- 第一组PH中约1/5患者静息PAWP升高,但代谢组学仍符合第一组PH。
- 高PAWP的第一组PH患者左心房功能和运动舒张储备优于Cpc-PH HFpEF。
- 静息PAWP单独用于区分第一组PH与HFpEF存在局限,需更综合诊断标准。
核心结论
- 约1/5经 adjudicated 的第一组肺动脉高压患者存在静息PAWP升高,尽管有严重肺血管功能障碍且代谢组学符合第一组PH。
- 这些患者代谢组学和生物学上不同于Cpc-PH HFpEF,左心房功能及运动舒张储备更好。
- 数据强调仅用静息PAWP区分第一组PH与HFpEF的局限性,呼吁建立更综合的临床诊断标准。
研究设计与样本
- 研究纳入PVDOMICS数据库中2016至2019年经 adjudicated 的第一组PH患者,按PAWP>15 mm Hg或正常分组,并与Cpc-PH HFpEF比较。
- 参与者接受动态右心导管检查和代谢组学分析。
- 结果在3个独立的第一组PH验证队列中验证,验证队列1和2采用运动右心导管,验证队列3采用静息右心导管。
主要发现
- 325例第一组PH患者中(73%女性,平均年龄53.0±14.3岁),15%(n=48)存在高PAWP。
- 与第一组PH+正常PAWP相比,第一组PH+高PAWP患者肥胖、左心室肥厚(P<0.0002)、左心室应变受损(P<0.0001)和左心室顺应性降低(P<0.0001)更明显,变化与Cpc-PH HFpEF(n=75)相当。
- 与Cpc-PH HFpEF相比,第一组PH+高PAWP患者左心房功能更好,表现为PAWP V波更低、左心房顺应性和左心房射血分数更高(所有P<0.0001)。
- 代谢组学显示第一组PH高PAWP与正常PAWP之间差异很小,但第一组PH+高PAWP与Cpc-PH HFpEF之间差异很大(在FDR P<0.05下100种代谢物改变)。
- 验证队列1(n=402)中18%的第一组PH存在高PAWP,运动PAWP反应介于Cpc-PH HFpEF和第一组PH+正常PAWP之间(交互P<0.0001);验证队列2(n=55)和3(n=787)中分别有22%和19%存在高PAWP。
临床怎么用
- 临床解读第一组PH患者时应关注静息PAWP升高的可能性,但不应仅凭PAWP>15 mm Hg排除第一组PH诊断。
- 对于静息PAWP升高的第一组PH患者,可结合左心房功能、运动负荷右心导管及代谢组学特征综合评估。
- 需开发更综合的临床诊断标准以区分第一组PH与HFpEF。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: With pulmonary hypertension (PH), a pulmonary artery wedge pressure (PAWP)>15 mm Hg is used to diagnose left heart dysfunction, but some patients with adjudicated group 1 PH demonstrate PAWP>15 mm Hg. The primary objective of the study was to evaluate group 1 PH with high PAWP>15 mm Hg. METHODS: Patients with adjudicated group 1 PH from PVDOMICS between 2016 and 2019 were separated into high PAWP(>15 mm Hg) or normal PAWP and compared with adjudicated combined pre- and postcapillary (Cpc) PH related to heart failure with preserved ejection fraction (HFpEF). Participants underwent dynamic right heart catheterization and metabolomics. Findings were validated in 3 independent cohorts with adjudicated group 1 PH (validation cohorts 1 and 2 with exercise right heart catheterization and validation cohort 3 with resting right heart catheterization). RESULTS: Of 325 patients with group 1 PH (73% women, mean age 53.0±14.3 years), 15% (n=48) had high PAWP. Group 1 PH+high PAWP demonstrated greater obesity, left ventricular hypertrophy (P<0.0002), left ventricular strain impairment (P<0.0001), and decreased left ventricular compliance (P<0.0001) compared with group 1 PH+normal PAWP, with changes comparable to Cpc-PH HFpEF (n=75). Compared with Cpc-PH HFpEF, left atrial function was better in group 1 PH+high PAWP with lower PAWP V wave, higher left atrial compliance, and left atrial ejection fraction (P<0.0001 for all). Metabolomics demonstrated little difference between group 1 PH with high versus normal PAWP but large differences between group 1 PH+high PAWP versus Cpc-PH HFpEF (100 metabolites altered at false discovery rate P<0.05). Elevated PAWP was also observed in 18% of group 1 PH in the validation cohort 1 (n=402), with exercise PAWP response intermediately abnormal in group 1 PH+high PAWP relative to Cpc-PH HFpEF and group 1 PH+normal PAWP (interaction P<0.0001). Elevated PAWP was similarly observed in 22% and 19% of group 1 PH in validation cohorts 2 (n=55) and 3 (n=787), respectively. CONCLUSIONS: Approximately 1 in 5 adjudicated patients with group 1 PH has elevation in resting PAWP despite severe pulmonary vascular dysfunction and metabolomics consistent with traditionally defined group 1 PH. Despite resting PAWP elevation, these patients with group 1 PH were metabolomically and biologically distinct from Cpc PH HFpEF, with better left atrial function and diastolic reserve during exercise. These data emphasize the limitations of using resting PAWP alone to separate group 1 PH from HFpEF and call for development of more integrated clinical diagnostic criteria.
引用
- Reddy YNV, Frantz RP, Miranda WR, et al. Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension. Circulation. 2026. PMID: 41685452. doi:10.1161/CIRCULATIONAHA.125.077606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。